Join        Login             Stock Quote

Pfizer (PFE) Announces Positive Results From Chantix, Pristiq Studies

 January 24, 2013 01:30 PM

(By Mani) Pharma giant Pfizer Inc. (NYSE: PFE) announced positive results from various clinical trials, sending its shares up nearly 2.5 percent on Thursday.

Pfizer said its smoke-cessation drug Chantix demonstrated efficacy in smokers who previously attempted to quit smoking with Chantix. The drug significantly increased continuous abstinence rates compared to placebo at weeks nine to 12, the last four weeks of treatment.

Chantix was approved by the FDA in May 2006 as an aid to smoking cessation treatment in adults 18 and older. Chantix has been shown to increase the likelihood of abstinence from smoking for as long as one year compared to treatment with placebo.

Separately, the company said a Phase 4 study showed that Pristiq could be used as a treatment option for Major Depressive Disorder (MDD) in adults. The study supports the efficacy of 50 mg/day and 100 mg/day doses of Pristiq compared with placebo over eight weeks of treatment in adult patients with MDD.

In another development, Pfizer said a Phase 4 study showed that higher dose of Toviaz offers greater efficacy in reducing urge urinary incontinence in patients with overactive bladder (OAB). The recommended starting dose of Toviaz is 4 mg once daily. Roughly 455 million adults worldwide, including 33 million American adults, are estimated to suffer from OAB symptoms.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

[Related -Six Stocks That Could Get An October Bump From The FDA]

At 1.29 pm ET, shares are trading 1.50 percent higher at $27.05 on the NYSE.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.